Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - fluconazole - capsule, hard - 150 milligram(s) - triazole derivatives; fluconazole

Bangladesh - English - DGDA (Directorate General of Drug Administration)

eskayef pharmaceuticals ltd., tongi,gazipur - pantoprazole - tablet - 20 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

eskayef pharmaceuticals ltd., tongi,gazipur - pantoprazole - tablet - 40 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

eskayef pharmaceuticals ltd., tongi,gazipur - pantoprazole - injection - 40 mg/vial

Bangladesh - English - DGDA (Directorate General of Drug Administration)

beximco pharmaceuticals ltd. - miconazole - oral gel - 20 mg/gm

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 2.5 mg - zolmitriptan orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use zolmitriptan orally disintegrating tablets are contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zolmitriptan in pregnant women. in reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated rates of major birth defects (2.2% to 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy. data animal data when zolmitriptan was administered to pregnant rats during the period of organogenesis at oral doses of 100, 400, and 1200 mg/kg/day (plasma exposures (aucs) ≈280, 1100, and 5000 times the human auc at the maximum recommended human dose (mrhd) of 10 mg/day), there was a dose-related increase in embryolethality. a no-effect dose for embryolethality was not established. when zolmitriptan was administered to pregnant rabbits during the period of organogenesis at oral doses of 3, 10, and 30 mg/kg/day (plasma aucs ≈1, 11, and 42 times the human auc at the mrhd), there were increases in embryolethality and in fetal malformations and variations. the no-effect dose for adverse effects on embryofetal development was associated with a plasma auc similar to that in humans at the mrhd. when female rats were given zolmitriptan during gestation, parturition, and lactation at oral doses of 25, 100, and 400 mg/kg/day (plasma aucs ≈70, 280, and 1100 times that in human at the mrhd), an increased incidence of hydronephrosis was found in the offspring. the no-effect dose was associated with a plasma auc ≈280 times that in humans at the mrhd. risk summary there are no data on the presence of zolmitriptan or its metabolites in human milk, the effects on the breastfed infant, or the effects of zolmitriptan and its metabolites on milk production. in rats, oral dosing with zolmitriptan resulted in levels in milk up to 4 times that in maternal plasma. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for zolmitriptan and any potential adverse effects on the breastfed infant from zolmitriptan or from the underlying maternal condition. the safety and effectiveness in pediatric patients have not been established. therefore, zolmitriptan is not recommended for use in patients under 18 years of age. one randomized, placebo-controlled clinical trial of zolmitriptan tablets (2.5, 5 and 10 mg) evaluated 696 pediatric patients (aged 12 to 17 years) with migraines. this study did not demonstrate the efficacy of zolmitriptan compared to placebo in the treatment of migraine in adolescents. adverse reactions in the adolescent patients treated with zolmitriptan were similar in nature and frequency to those reported in clinical trials in adults treated with zolmitriptan. zolmitriptan has not been studied in pediatric patients less than 12 years old. in the postmarketing experience with triptans, including zolmitriptan, there were no additional adverse reactions seen in pediatric patients that were not seen in adults. clinical studies of zolmitriptan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. a cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) prior to receiving zolmitriptan [see warnings and precautions (5.1) ]. the pharmacokinetics of zolmitriptan were similar in geriatric patients (aged > 65 years) compared to younger patients [see clinical pharmacology (12.3) ]. after oral zolmitriptan administration, zolmitriptan blood levels were increased in patients with moderate to severe hepatic impairment, and significant elevation in blood pressure was observed in some of these patients [see warnings and precautions (5.8) ]. therefore, adjust the zolmitriptan dose and administer with caution in patients with moderate or severe hepatic impairment [see dosage and administration (2.3), clinical pharmacology (12) ].

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - olmesartan medoxomil; amlodipine besilate - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - olmesartan medoxomil; amlodipine - film-coated tablet - 20 mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - olmesartan medoxomil; amlodipine - film-coated tablet - 40 mg/5 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ireland - English - HPRA (Health Products Regulatory Authority)

menarini international operations luxembourg s.a. - olmesartan medoxomil; amlodipine - film-coated tablet - 40mg/10 milligram(s) - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine